Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.

Cancer science - 1 Nov 2018

Tsai Hui-Jen, Jiaang Weir-Torn, Shih Neng-Yao, Fletcher Jonathan A, Lin Ming-Jon, Yang Ming-Yu, Chen Chiung-Tong, Hsu Tsu-An John, Wu Chun-Chieh, Lin Hui-You, Chen Li-Tzong

Abstract excerpt

Gastrointestinal stromal tumor (GIST) is a type of KIT-driven cancer. KIT gene mutations are found in approximately 80% of GISTs, and most of these mutations occur in exon 9 and exon 11. Imatinib has been successfully used as a first-line treatment for advanced GIST, with a significant improvement in progression-free survival (PFS) and overall survival. However, disease progression might develop due to primary or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Gene Expression Regulation, Neoplastic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30142229
DOI: 10.1111/cas.13773
PMCID: PMC6215875

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.PMID 30142229Read ↗

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.Semantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.Semantic proximity Read ↗

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.Semantic proximity Read ↗

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.Semantic proximity Read ↗

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.Semantic proximity Read ↗

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read ↗

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.